Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS)
CNY 18.4
(-0.38%)
CNY 18.4
(-0.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 271.42 Million CNY | 19.81% |
| 2022 | 222 Million CNY | 34.39% |
| 2021 | 167.72 Million CNY | 4.87% |
| 2020 | 157.73 Million CNY | 19.26% |
| 2019 | 131.17 Million CNY | 22.2% |
| 2018 | 108.16 Million CNY | 1.87% |
| 2017 | 105.73 Million CNY | -8.8% |
| 2016 | 111.54 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 72.31 Million CNY | -2.26% |
| 2024 Q2 | 60.58 Million CNY | -3.13% |
| 2024 Q1 | 63.64 Million CNY | 11.62% |
| 2023 Q3 | 59.77 Million CNY | 5.91% |
| 2023 Q1 | 51.57 Million CNY | 27.46% |
| 2023 FY | - CNY | 19.81% |
| 2023 Q2 | 56.43 Million CNY | 9.43% |
| 2023 Q4 | 55.98 Million CNY | -6.33% |
| 2022 Q3 | 40.56 Million CNY | -5.1% |
| 2022 FY | - CNY | 34.39% |
| 2022 Q4 | 40.46 Million CNY | -0.27% |
| 2022 Q2 | 42.75 Million CNY | -21.08% |
| 2022 Q1 | 54.16 Million CNY | 69.18% |
| 2021 Q4 | 32.01 Million CNY | 20.57% |
| 2021 Q3 | 26.55 Million CNY | -34.66% |
| 2021 Q1 | 21.36 Million CNY | -25.52% |
| 2021 Q2 | 40.64 Million CNY | 90.19% |
| 2021 FY | - CNY | 4.87% |
| 2020 Q2 | 43.86 Million CNY | 127.0% |
| 2020 FY | - CNY | 19.26% |
| 2020 Q4 | 28.69 Million CNY | 14.11% |
| 2020 Q3 | 25.14 Million CNY | -42.68% |
| 2020 Q1 | 19.32 Million CNY | -40.16% |
| 2019 Q3 | 32.28 Million CNY | 7.61% |
| 2019 FY | - CNY | 22.2% |
| 2019 Q4 | 32.28 Million CNY | 0.0% |
| 2019 Q2 | 30 Million CNY | 0.0% |
| 2019 Q1 | 30 Million CNY | 0.0% |
| 2018 FY | - CNY | 1.87% |
| 2017 FY | - CNY | -8.8% |
| 2016 FY | - CNY | 0.0% |